Study of Adding AMG 479 to First Line Chemotherapy in Patients With Optimally Debulked Epithelial Ovarian Cancer

Summary

This study will determine the value of adding AMG 479 (fully human monoclonal antibody against IGF-1R) to paclitaxel and carboplatin first line chemotherapy in patients with optimally debulked (\<1 cm) FIGO stage III and IV (positive pleural cytology only) ovarian epithelial (including fallopian tube and primary peritoneal) carcinoma.

Timeline

Start

2009-01

Primary completion

2013-09

Completion

2014-11

Outcome

Outcome not reported

Stopped: “The steering committee of the TRIO014 study has taken the decision to stop the TRIO014 trial.”

Drugs

Indications